不安定性アンギナにおけるヘパリンと血栓解離のランダム化試験
T L Schreiber1, D Rizik, C White
1William Beaumont Hospital, Royal Oak, Mich. 48073-6769.
Circulation
|November 1, 1992
まとめ
静脈注入のウロキナーゼは,標準ヘパリン療法と比較して,不安定な胸痛患者の臨床的利益を示さなかった. この血栓解消療法,アスピリンを併用しても,96時間以内に新たな心筋梗塞や死亡を防ぐことはできませんでした.
科学分野:
- 心臓病学 心臓病学
- 血栓性疾患 血栓性疾患 血栓性疾患 血栓性疾患 血栓性疾患 血栓性疾患 血栓性疾患 血栓性疾患
- 急性冠動脈症候群とは
背景:
- 不安定性アンギナに対する静脈注射の血栓解消薬療法の有効性は不明である.
- 不安定性アンギナは,急性心筋梗塞と病原学的類似性を共有し,その場合,血栓解析は成功します.
研究 の 目的:
- 静脈注射ウロキナーゼの臨床的効果を従来の抗血栓剤療法と比較する.
- 心筋梗塞,難治性胸痛,または96時間以内に死亡に至る進行の予防を評価する.
主な方法:
- 149人の不安定な胸痛患者は3つのグループにランダムに分けられました.
- グループA:ウロキナーゼ + ヘパリン. グループB:ウロキナーゼ+アスピリン. グループC:プラセボ+ヘパリン.
- 主要エンドポイント:96時間の臨床状態.
主要な成果:
- グループ間のベースラインの特徴の有意な差はありません.
- 軽微な反応はウロキナーゼ群では高かったが,大きな出血では有意な違いはなかった.
- 96時間後の新規心筋梗塞,難治性胸痛,または全体的な心筋梗塞における有意な違いはありません.
結論:
- ヘパリンまたはアスピリンを併用した高用量の静脈注射ウロキナーゼは,不安定な胸痛患者では安全です.
- ウロキナーゼは,標準ヘパリン療法に比べて臨床上の利点を与えない.
- ウロキナゼの有害な影響を排除することはできません.
さらに関連する動画
04:52Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique
Published on: September 13, 2022
08:33A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
Published on: January 5, 2024
関連する概念動画
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...